Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Colistimethate sodium inhaled - Zambon

Drug Profile

Colistimethate sodium inhaled - Zambon

Alternative Names: Inhaled colistimethate sodium - Zambon; Promixin; ZP-044

Latest Information Update: 20 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Profile Pharma
  • Developer Zambon SpA
  • Class Antibacterials; Polymixins
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Phase III Pseudomonal infections

Most Recent Events

  • 11 Dec 2018 Phase-III clinical trials in Pseudomonal infections in Poland (Inhalation) (EudraCT2016-004558-13) before December 2018
  • 11 Dec 2018 Phase-III clinical trials in Pseudomonal infections in Portugal, Germany (Inhalation) (NCT03093974)
  • 11 Dec 2018 Colistimethate sodium inhaled receives Fast track status from the US FDA for Non-Cystic Fibrosis Bronchiectasis (NCFB) colonized with Pseudomonas aeruginosa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top